Faculty Information |
|
Article types | Original article |
Language | English |
Refereed paper | Refereed |
Title | A novel prostanoid EP1 receptor antagonist, ONO-8539, reduces acid-induced heartburn symptoms in healthy male volunteers: a randomized clinical trial. |
Journal | Formal name:Journal of gastroenterology Abbreviation:J Gastroenterol ISSN code:1435-5922(Electronic)0944-1174(Linking) |
Domestic / Foregin | Foregin |
Volume, Number, Page | 52(10),pp.1081-1089 |
Papers・Author | Kondo Takashi, Sei Hiroo, Yamasaki Takahisa, Tomita Toshihiko, Ohda Yoshio, Oshima Tadayuki, Fukui Hirokazu, Watari Jiro, Miwa Hiroto |
Publication date | 2017/10 |
Papers・Description | BACKGROUND:Patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) have unmet clinical needs. Recently, we reported that esophageal prostaglandin E2METHODS:This prospective, double-blind, placebo-controlled, two-period crossover study was performed in 20 healthy male subjects. The novel prostanoid EP1 receptor antagonist, ONO-8539 (450 mg), was administered once 4 h prior to acid perfusion test. During the test, hydrochloric acid (0.15 mol l-1RESULTS:ONO-8539 significantly reduced a total heartburn symptom score, not other upper GI symptom scores, during acid perfusion compared with placebo (AUC for heartburn, 85.0 ± 10.6 for placebo and 56.5 ± 7.2 for ONO-8539; P <0.01), and significantly extended the time to first sensation of heartburn compared with placebo (5.7 ± 4.3 min for placebo and 9.7 ± 7.2 min for ONO-8539; P < 0.05).CONCLUSIONS:ONO-8539 attenuated acid-induced heartburn in healthy male subjects, suggesting that EP1 receptors play a role in generation of heartburn symptoms. ONO-8539 is a potential novel therapeutic option for controlling heartburn symptoms in GERD patients. Clinical Trials Registry No: UMIN000015753. |
DOI | 10.1007/s00535-017-1308-3 |
PMID | 28120127 |